JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Overview Fund Activity
Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

113 hedge funds and large institutions have $285M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 41 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
113
Holders Change
-11
Holders Change %
-8.87%
% of All Funds
1.79%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
10
Increased
34
Reduced
41
Closed
20
Calls
$390K
Puts
$410K
Net Calls
-$20K
Net Calls Change
-$415K

Top Buyers

1
RI
1
RTW Investments
New York
$31.8M
2
Morgan Stanley
2
Morgan Stanley
New York
$10.4M
3
Assenagon Asset Management
3
Assenagon Asset Management
Luxembourg
$9.94M
4
ACP
4
Acuta Capital Partners
California
$5.52M
5
CAC
5
Cowen and Company
New York
$3.9M

Top Sellers

1
WP
1
Woodline Partners
California
$0
2
TGI
2
TRV GP II
Massachusetts
$9.15M
3
CS
3
Candriam SCA
Luxembourg
$0
4
Goldman Sachs
4
Goldman Sachs
New York
$2.66M
5
Barclays
5
Barclays
United Kingdom
$3.12M
Name Holding Trade Value Shares
Change 		Shares
Change %
Axa
126
Axa
France
– -$126K -15,100 Closed
Squarepoint
127
Squarepoint
New York
– -$92K -11,054 Closed
MLICM
128
Metropolitan Life Insurance Company (MetLife)
New York
– -$64.1K -7,678 Closed
MIM
129
MetLife Investment Management
New Jersey
– -$14K -1,671 Closed
QT
130
Quantbot Technologies
New York
– -$4K -561 Closed
RPCONE
131
Retirement Planning Company of New England
Rhode Island
– -$3K -420 Closed
2 3 4 5
6